76-Year-Old Patient, Not on Antithrombotic Therapy, Presenting to ED After Ground-Level Fall (Glasgow Coma Scale of 15)

March 25, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), antithrombotic therapy was not linked to increased incidence of traumatic intracranial hemorrhage on CT in adult patients, although the therapy did show association with hematoma expansion at follow-up.

“The findings suggest, in patients with good neurological status after ground-level fall, application of a similar strategy for selecting patients for initial head CT, regardless of antithrombotic therapy use,” wrote first author Zeynep Vardar, M.D., at the University of Massachusetts Medical Center in Worcester. “If initial head CT shows traumatic intracranial hemorrhage, early follow-up head CT should be systematically performed in those on antithrombotic therapy though possibly deferred in other patients.”

Vardar and colleagues’ retrospective case-control study included 1,630 patients (693 female, 937 male; mean age, 80 years) who underwent head CT after presenting to the emergency department (ED) with ground-level fall (Glasgow Coma Scale ≥ 14 and no focal neurological deficit) between January 1 and December 31, 2020. Initial head CT examinations were reviewed for traumatic intracranial hemorrhage characteristics and follow-up head CT examinations (performed within 24 hours) were reviewed for hematoma expansion, with clinical outcomes extracted from medical records.

The frequency of intracranial hemorrhage after ground-level fall with good neurological status was not significantly different between patients on antithrombotic therapy and those not on antithrombotic therapy (4.4% vs 3.1% respectively, p = .24). However, hematoma expansion occurred more frequently in patients on antithrombotic therapy (26.2% vs 4.8%, p = .04).

Also noting no significant difference between patients on anticoagulant therapy alone, antiplatelet therapy alone, or both, “the frequency of midline shift and regional mass effect was not significantly different between patients on antithrombotic therapy and control patients,” the authors of this AJR article added.

For more information: www.arrs.org


Related Content

News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
News | Enterprise Imaging

Mar. 9, 2026 — GE HealthCare recently announced that View, the viewer within the Genesis Radiology Workspace, has ...

Time March 12, 2026
arrow
News | Lung Imaging

March 11, 2026 — Noah Medical has announced the publication of the MATCH 2 study in the international, peer-reviewed ...

Time March 12, 2026
arrow
News | Computed Tomography (CT)

March 5, 2026 — At ECR 2026, Royal Philips introduced Rembra, its next-generation radiology CT system designed for the ...

Time March 09, 2026
arrow
News | FDA

Mar. 9, 2026 — GE HealthCare's View, the powerful viewer within the Genesis Radiology Workspace, has received 510(k) ...

Time March 09, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | HIMSS

March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...

Time March 06, 2026
arrow
News | Radiology Business

March 5, 2026 — Cassling is now accepting applications for the 2026 Imaging for Impact Award, a national recognition ...

Time March 05, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
Subscribe Now